FDA Grants Fast Track Designation to SOT106 for Soft Tissue Sarcoma Treatment
“Soft tissue sarcomas (STS) remain a major unmet medical need, where decades of therapeutic progress have yet to translate into meaningful improvements for patients with advanced or recurrent disease,” said Vivi Boura, M.D., chief medical officer of SOTIO. “Receiving Fast Track Designation for SOT106 is an important regulatory milestone that reinforces this program’s potential to improve outcomes for patients facing these difficult-to-treat cancers. As we advance SOT106 toward the clinic, we aim to translate its differentiated design and LRRC15-targeting strategy into a novel therapeutic approach with the potential to offer a new treatment option for patients across multiple soft tissue sarcoma subtypes.”
Share:
More News
Dr Jing He, Head of R&D China, AstraZeneca, said: “These positive data underscore the pivotal role of ORPATHYS® in intercepting MET-driven resistance early in the treatment journey. By combining the targeted precision of ORPATHYS® with backbone TAGRISSO®, SANOVO demonstrates a meaningful clinical advancement for treatment-naïve patients with MET overexpression and
“ADI-212 marks an important milestone in Adicet’s strategy to address the complexity of solid tumors and represents an important addition to our portfolio of allogeneic gamma delta 1 cell therapies and in vivo CAR T programs,” said Blake Aftab, Ph.D., Chief Scientific Officer of Adicet Bio. “Designed as a single
“Any decision concerning clinical trials is made with utmost care, keeping patients as our highest priority,” said Prof. Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. “While this outcome is not what we had envisioned for mRNA as a monotherapy in colorectal cancer, it provides scientific insight into
“These results reinforce our confidence that Ziihera is the new HER2-targeted backbone therapy in first-line HER2+ advanced GEA, replacing trastuzumab and extending survival beyond the current standard of care,” said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals.